Form 8-K PTC THERAPEUTICS, INC. For: May 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'
May 17, 2023 2:43 PM EDTCiti analyst David Lebowitz raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $70.00 (from $67.00) while maintaining a Buy rating.
The analyst comments "Today, PTCT held a call to discuss positive sepiapterin (PTC923) pivotal data in phenylketonuria (PKU) and competitive dynamics. Given the deeper... More
